Skip to main content
Top
Published in: BMC Musculoskeletal Disorders 1/2022

Open Access 01-12-2022 | Osteoarthrosis | Research

Patient characteristics, pain treatment patterns, and incidence of total joint replacement in a US population with osteoarthritis

Authors: Mayura Shinde, Carla Rodriguez-Watson, Tancy C. Zhang, David S. Carrell, Aaron B. Mendelsohn, Young Hee Nam, Amanda Carruth, Kenneth R. Petronis, Cheryl N. McMahill-Walraven, Aziza Jamal-Allial, Vinit Nair, Pamala A. Pawloski, Anne Hickman, Mark T. Brown, Jennie Francis, Ken Hornbuckle, Jeffrey S. Brown, Jingping Mo

Published in: BMC Musculoskeletal Disorders | Issue 1/2022

Login to get access

Abstract

Background

Currently available medications for chronic osteoarthritis pain are only moderately effective, and their use is limited in many patients because of serious adverse effects and contraindications. The primary surgical option for osteoarthritis is total joint replacement (TJR). The objectives of this study were to describe the treatment history of patients with osteoarthritis receiving prescription pain medications and/or intra-articular corticosteroid injections, and to estimate the incidence of TJR in these patients.

Methods

This retrospective, multicenter, cohort study utilized health plan administrative claims data (January 1, 2013, through December 31, 2019) of adult patients with osteoarthritis in the Innovation in Medical Evidence Development and Surveillance Distributed Database, a subset of the US FDA Sentinel Distributed Database. Patients were analyzed in two cohorts: those with prevalent use of “any pain medication” (prescription non-steroidal anti-inflammatory drugs [NSAIDs], opioids, and/or intra-articular corticosteroid injections) using only the first qualifying dispensing (index date); and those with prevalent use of “each specific pain medication class” with all qualifying treatment episodes identified.

Results

Among 1 992 670 prevalent users of “any pain medication”, pain medications prescribed on the index date were NSAIDs (596 624 [29.9%] patients), opioids (1 161 806 [58.3%]), and intra-articular corticosteroids (323 459 [16.2%]). Further, 92 026 patients received multiple pain medications on the index date, including 71 632 (3.6%) receiving both NSAIDs and opioids. Altogether, 20.6% of patients used an NSAID at any time following an opioid index dispensing and 17.2% used an opioid following an NSAID index dispensing. The TJR incidence rates per 100 person-years (95% confidence interval [CI]) were 3.21 (95% CI: 3.20–3.23) in the “any pain medication” user cohort, and among those receiving “each specific pain medication class” were NSAIDs, 4.63 (95% CI: 4.58–4.67); opioids, 7.45 (95% CI: 7.40–7.49); and intra-articular corticosteroids, 8.05 (95% CI: 7.97–8.13).

Conclusions

In patients treated with prescription medications for osteoarthritis pain, opioids were more commonly prescribed at index than NSAIDs and intra-articular corticosteroid injections. Of the pain medication classes examined, the incidence of TJR was highest in patients receiving intra-articular corticosteroids and lowest in patients receiving NSAIDs.
Appendix
Available only for authorised users
Literature
1.
go back to reference GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204–22.CrossRef GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204–22.CrossRef
2.
go back to reference Duenas M, Ojeda B, Salazar A, Mico JA, Failde I. A review of chronic pain impact on patients, their social environment and the health care system. J Pain Res. 2016;9:457–67.CrossRef Duenas M, Ojeda B, Salazar A, Mico JA, Failde I. A review of chronic pain impact on patients, their social environment and the health care system. J Pain Res. 2016;9:457–67.CrossRef
3.
go back to reference Barbour KE, Helmick CG, Boring M, Brady TJ. Vital signs: prevalence of doctor-diagnosed arthritis and arthritis-attributable activity limitation - United States, 2013–2015. MMWR Morb Mortal Wkly Rep. 2017;66(9):246–53. Barbour KE, Helmick CG, Boring M, Brady TJ. Vital signs: prevalence of doctor-diagnosed arthritis and arthritis-attributable activity limitation - United States, 2013–2015. MMWR Morb Mortal Wkly Rep. 2017;66(9):246–53.
4.
go back to reference Cross M, Smith E, Hoy D, Nolte S, Ackerman I, Fransen M, et al. The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014;73(7):1323–30.CrossRef Cross M, Smith E, Hoy D, Nolte S, Ackerman I, Fransen M, et al. The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014;73(7):1323–30.CrossRef
5.
go back to reference Nalamachu SR, Robinson RL, Viktrup L, Cappelleri JC, Bushmakin AG, Tive L, et al. Multimodal treatment patterns for osteoarthritis and their relationship to patient-reported pain severity: a cross-sectional survey in the United States. J Pain Res. 2020;13:3415–25. Nalamachu SR, Robinson RL, Viktrup L, Cappelleri JC, Bushmakin AG, Tive L, et al. Multimodal treatment patterns for osteoarthritis and their relationship to patient-reported pain severity: a cross-sectional survey in the United States. J Pain Res. 2020;13:3415–25.
6.
go back to reference Conaghan PG, Cook AD, Hamilton JA, Tak PP. Therapeutic options for targeting inflammatory osteoarthritis pain. Nat Rev Rheumatol. 2019;15(6):355–63.CrossRef Conaghan PG, Cook AD, Hamilton JA, Tak PP. Therapeutic options for targeting inflammatory osteoarthritis pain. Nat Rev Rheumatol. 2019;15(6):355–63.CrossRef
7.
go back to reference Martel-Pelletier J, Barr AJ, Cicuttini FM, Conaghan PG, Cooper C, Goldring MB, et al. Osteoarthritis. Nat Rev Dis Primers. 2016;2:16072. Martel-Pelletier J, Barr AJ, Cicuttini FM, Conaghan PG, Cooper C, Goldring MB, et al. Osteoarthritis. Nat Rev Dis Primers. 2016;2:16072.
8.
go back to reference Watt FE, Gulati M. New drug treatments for osteoarthritis: what is on the horizon? Eur Med J Rheumatol. 2017;2(1):50–8. Watt FE, Gulati M. New drug treatments for osteoarthritis: what is on the horizon? Eur Med J Rheumatol. 2017;2(1):50–8.
9.
go back to reference Kolasinski SL, Neogi T, Hochberg MC, Oatis C, Guyatt G, Block J, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Care Res (Hoboken). 2020;72(2):149–62.CrossRef Kolasinski SL, Neogi T, Hochberg MC, Oatis C, Guyatt G, Block J, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Care Res (Hoboken). 2020;72(2):149–62.CrossRef
10.
go back to reference Gandhi K, Wei W, Huang A, Wang L, Iyer R, Katz NP. A real-world study using claims data to evaluate possible failure of opioid treatment regimens among patients with hip and/or knee osteoarthritis in the US. Clinicoecon Outcomes Res. 2020;12:285–97. Gandhi K, Wei W, Huang A, Wang L, Iyer R, Katz NP. A real-world study using claims data to evaluate possible failure of opioid treatment regimens among patients with hip and/or knee osteoarthritis in the US. Clinicoecon Outcomes Res. 2020;12:285–97.
11.
go back to reference Price AJ, Alvand A, Troelsen A, Katz JN, Hooper G, Gray A, et al. Knee replacement. Lancet. 2018;392(10158):1672–82.CrossRef Price AJ, Alvand A, Troelsen A, Katz JN, Hooper G, Gray A, et al. Knee replacement. Lancet. 2018;392(10158):1672–82.CrossRef
12.
go back to reference Maradit Kremers H, Larson DR, Crowson CS, Kremers WK, Washington RE, Steiner CA, et al. Prevalence of total hip and knee replacement in the United States. J Bone Joint Surg Am. 2015;97(17):1386–97. Maradit Kremers H, Larson DR, Crowson CS, Kremers WK, Washington RE, Steiner CA, et al. Prevalence of total hip and knee replacement in the United States. J Bone Joint Surg Am. 2015;97(17):1386–97.
14.
go back to reference Ball R, Robb M, Anderson SA, Dal Pan G. The FDA’s sentinel initiative–a comprehensive approach to medical product surveillance. Clin Pharmacol Ther. 2016;99(3):265–8. Ball R, Robb M, Anderson SA, Dal Pan G. The FDA’s sentinel initiative–a comprehensive approach to medical product surveillance. Clin Pharmacol Ther. 2016;99(3):265–8.
15.
go back to reference Platt R, Brown JS, Robb M, McClellan M, Ball R, Nguyen MD, et al. The FDA Sentinel Initiative - an evolving national resource. N Engl J Med. 2018;379(22):2091–3. Platt R, Brown JS, Robb M, McClellan M, Ball R, Nguyen MD, et al. The FDA Sentinel Initiative - an evolving national resource. N Engl J Med. 2018;379(22):2091–3.
19.
go back to reference Gore M, Tai KS, Sadosky A, Leslie D, Stacey BR. Clinical comorbidities, treatment patterns, and direct medical costs of patients with osteoarthritis in usual care: a retrospective claims database analysis. J Med Econ. 2011;14(4):497–507.CrossRef Gore M, Tai KS, Sadosky A, Leslie D, Stacey BR. Clinical comorbidities, treatment patterns, and direct medical costs of patients with osteoarthritis in usual care: a retrospective claims database analysis. J Med Econ. 2011;14(4):497–507.CrossRef
20.
go back to reference Postler A, Ramos AL, Goronzy J, Gunther KP, Lange T, Schmitt J, et al. Prevalence and treatment of hip and knee osteoarthritis in people aged 60 years or older in Germany: an analysis based on health insurance claims data. Clin Interv Aging. 2018;13:2339–49.CrossRef Postler A, Ramos AL, Goronzy J, Gunther KP, Lange T, Schmitt J, et al. Prevalence and treatment of hip and knee osteoarthritis in people aged 60 years or older in Germany: an analysis based on health insurance claims data. Clin Interv Aging. 2018;13:2339–49.CrossRef
21.
go back to reference Katz JN, Arant KR, Loeser RF. Diagnosis and treatment of hip and knee osteoarthritis: a review. JAMA. 2021;325(6):568–78. Katz JN, Arant KR, Loeser RF. Diagnosis and treatment of hip and knee osteoarthritis: a review. JAMA. 2021;325(6):568–78.
22.
go back to reference Block JA, Cherny D. Management of knee osteoarthritis: what internists need to know. Med Clin North Am. 2021;105(2):367–85. Block JA, Cherny D. Management of knee osteoarthritis: what internists need to know. Med Clin North Am. 2021;105(2):367–85.
23.
go back to reference Cao P, Li Y, Tang Y, Ding C, Hunter DJ. Pharmacotherapy for knee osteoarthritis: current and emerging therapies. Expert Opin Pharmacother. 2020;21(7):797–809.CrossRef Cao P, Li Y, Tang Y, Ding C, Hunter DJ. Pharmacotherapy for knee osteoarthritis: current and emerging therapies. Expert Opin Pharmacother. 2020;21(7):797–809.CrossRef
24.
go back to reference Dysart S, Utkina K, Stong L, Nelson W, Sacks N, Healey B, et al. Insights from real-world analysis of treatment patterns in patients with newly diagnosed knee osteoarthritis. Am Health Drug Benefits. 2021;14(2):56–62. Dysart S, Utkina K, Stong L, Nelson W, Sacks N, Healey B, et al. Insights from real-world analysis of treatment patterns in patients with newly diagnosed knee osteoarthritis. Am Health Drug Benefits. 2021;14(2):56–62.
25.
go back to reference Cho SK, Jung SY, Choi S, Im SG, Kim H, Choi WS, et al. Factors related to the use of opioids as early treatment in patients with knee osteoarthritis. Arthritis Res Ther. 2019;21(1):222.CrossRef Cho SK, Jung SY, Choi S, Im SG, Kim H, Choi WS, et al. Factors related to the use of opioids as early treatment in patients with knee osteoarthritis. Arthritis Res Ther. 2019;21(1):222.CrossRef
26.
go back to reference Park HR, Cho SK, Im SG, Jung SY, Kim D, Jang EJ, et al. Treatment patterns of knee osteoarthritis patients in Korea. Korean J Intern Med. 2019;34(5):1145–53.CrossRef Park HR, Cho SK, Im SG, Jung SY, Kim D, Jang EJ, et al. Treatment patterns of knee osteoarthritis patients in Korea. Korean J Intern Med. 2019;34(5):1145–53.CrossRef
27.
go back to reference Berger A, Bozic K, Stacey B, Edelsberg J, Sadosky A, Oster G. Patterns of pharmacotherapy and health care utilization and costs prior to total hip or total knee replacement in patients with osteoarthritis. Arthritis Rheum. 2011;63(8):2268–75.CrossRef Berger A, Bozic K, Stacey B, Edelsberg J, Sadosky A, Oster G. Patterns of pharmacotherapy and health care utilization and costs prior to total hip or total knee replacement in patients with osteoarthritis. Arthritis Rheum. 2011;63(8):2268–75.CrossRef
28.
go back to reference Jin Y, Solomon DH, Franklin PD, Lee YC, Lii J, Katz JN, et al. Patterns of prescription opioid use before total hip and knee replacement among US Medicare enrollees. Osteoarthritis Cartilage. 2019;27(10):1445–53.CrossRef Jin Y, Solomon DH, Franklin PD, Lee YC, Lii J, Katz JN, et al. Patterns of prescription opioid use before total hip and knee replacement among US Medicare enrollees. Osteoarthritis Cartilage. 2019;27(10):1445–53.CrossRef
29.
go back to reference Singh JA. Epidemiology of knee and hip arthroplasty: a systematic review. Open Orthop J. 2011;5:80–5.CrossRef Singh JA. Epidemiology of knee and hip arthroplasty: a systematic review. Open Orthop J. 2011;5:80–5.CrossRef
30.
go back to reference Bager CL, Karsdal M, Bihlet A, Thudium C, Byrjalsen I, Bay-Jensen AC. Incidence of total hip and total knee replacements from the prospective epidemiologic risk factor study: considerations for event driven clinical trial design. BMC Musculoskelet Disord. 2019;20(1):303.CrossRef Bager CL, Karsdal M, Bihlet A, Thudium C, Byrjalsen I, Bay-Jensen AC. Incidence of total hip and total knee replacements from the prospective epidemiologic risk factor study: considerations for event driven clinical trial design. BMC Musculoskelet Disord. 2019;20(1):303.CrossRef
31.
go back to reference Losina E, Song S, Bensen GP, Katz JN. Opioid use among Medicare beneficiaries with knee osteoarthritis: prevalence and correlates of chronic use. Arthritis Care Res (Hoboken). 2021. Losina E, Song S, Bensen GP, Katz JN. Opioid use among Medicare beneficiaries with knee osteoarthritis: prevalence and correlates of chronic use. Arthritis Care Res (Hoboken). 2021.
32.
go back to reference Mikosz CA, Zhang K, Haegerich T, Xu L, Losby JL, Greenspan A, et al. Indication-specific opioid prescribing for US patients with medicaid or private insurance, 2017. JAMA Netw Open. 2020;3(5):e204514. Mikosz CA, Zhang K, Haegerich T, Xu L, Losby JL, Greenspan A, et al. Indication-specific opioid prescribing for US patients with medicaid or private insurance, 2017. JAMA Netw Open. 2020;3(5):e204514.
Metadata
Title
Patient characteristics, pain treatment patterns, and incidence of total joint replacement in a US population with osteoarthritis
Authors
Mayura Shinde
Carla Rodriguez-Watson
Tancy C. Zhang
David S. Carrell
Aaron B. Mendelsohn
Young Hee Nam
Amanda Carruth
Kenneth R. Petronis
Cheryl N. McMahill-Walraven
Aziza Jamal-Allial
Vinit Nair
Pamala A. Pawloski
Anne Hickman
Mark T. Brown
Jennie Francis
Ken Hornbuckle
Jeffrey S. Brown
Jingping Mo
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Musculoskeletal Disorders / Issue 1/2022
Electronic ISSN: 1471-2474
DOI
https://doi.org/10.1186/s12891-022-05823-7

Other articles of this Issue 1/2022

BMC Musculoskeletal Disorders 1/2022 Go to the issue